Physician profile
Michael D Huffman
NPI 1386607182
$10,673.63
in general payments reported to CMS, 2019-2025
44 companies · $1,073 in 2025
The $1,073 reported for 2025 was more than what 87% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,360 · 2020: $1,948 · 2021: $2,156 · 2022: $1,537 · 2023: $1,261 · 2024: $1,338 · 2025: $1,073.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,673.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,672.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,540.07 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $1,356.09 | 2019-2025 | |
| Lilly USA, LLC | $1,216.55 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Astrazeneca Pharmaceuticals LP | $1,102.62 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Amgen INC. | $885.31 | 2019-2025 | Evenity, Prolia |
| Boehringer Ingelheim Pharmaceuticals, INC. | $689.41 | 2019-2025 | Jardiance |
| Pfizer INC. | $638.21 | 2019-2025 | |
| Esperion Therapeutics, INC. | $565.13 | 2020-2024 | Nexletol |
| Sanofi-Aventis U.S. LLC | $306.34 | 2020-2024 | |
| Astellas Pharma US INC | $292.12 | 2023-2025 | Veozah, Myrbetriq |
| Allergan, INC. | $254.91 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $232.22 | 2020-2025 | |
| Biohaven Pharmaceuticals, INC. | $215.67 | 2020-2021 | |
| Amarin Pharma, INC. | $142.74 | 2020-2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $127.04 | 2022 |
Show all 44 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Huffman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.